Evaluation of body composition during low-dose estrogen oral contraceptives treatment.
OBJECTIVE
To determine in a prospective study if the use of two low-dose estrogen oral contraceptives is associated with changes in weight or body composition.


METHODS
80 outpatients referring to the family planning service, aged 18-43 years were randomly assigned to a treatment with the EE/desogestrel or EE/gestodene association, 20 patients with IUD, aged 26-40 years, were selected as a control group. Anthropometric data and body composition were taken at enrollment and after 6 and 12 months.


METHODS
Anthropometric measurements included body mass index (BMI), body composition estimated by mean of Bioelectrical Impendance Analysis (BIA).


RESULTS
In the three groups weight, BMI, and total body water (TBW), and body cellular mass (BCM) remained unchanged during the study period.


CONCLUSIONS
The use of EE/desogestrel and EE/gestodene is not associated with significant variations of body weight and body composition during one year treatment.
Franchini
M
M
Obstetric and Gynecology Department, S.M. Annunziata Hospital, Florence, Italy.
Caruso
C
C
Nigrelli
S
S
Poggiali
C
C
D000293:Adolescent; D000328:Adult; D000886:Anthropometry; D001823:Body Composition / Q000187:drug effects*; D003278:Contraceptives, Oral, Hormonal / Q000627:therapeutic use*; D003280:Contraceptives, Oral, Synthetic / Q000627:therapeutic use*; D017135:Desogestrel / Q000627:therapeutic use; D045166:Estradiol Congeners / Q000627:therapeutic use*; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D009652:Norpregnenes / Q000627:therapeutic use; D045167:Progesterone Congeners / Q000627:therapeutic use*; D011446:Prospective Studies
D003278:Contraceptives, Oral, Hormonal; D003280:Contraceptives, Oral, Synthetic; D045166:Estradiol Congeners; D009652:Norpregnenes; D045167:Progesterone Congeners; C033273:Gestodene; D004997:Ethinyl Estradiol; D017135:Desogestrel